Nilotinib for Treatment of Newly Diagnosed Chronic Phase, Philadelphia Chromosome-Positive, CML

Imatinib was one of the first rationally designed drugs to specifically target the BCR-ABL fusion gene found in CML. Unfortunately, many patients eventually develop resistance to Imatinib. Nilotinib is a new drug designed to treat Imatinib-resistant CML. In this study, 71% of patients responded to Nilotinib compared to only 44% with Imatinib, and there were fewer progressions to accelerated or blast phase  (including clonal evolution), with Nilotinib. I like this approach because it focuses on improving the efficiency of a well established targeted drug, without the harsh side effects of standard chemo/radiation therapy.
Nilotinib Versus Imatinib for the Treatment of Patients with Newly Diagnosed Chronic Phase, Philadelphia Chromosome-Positive, Chronic Myeloid Leukaemia: 24-Month Minimum Follow-Up of the Phase 3 Randomised ENESTnd Trial.


Speak Your Mind

*